A First-in-Human Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Oral Dose Study of Novel Antimalarial Spiroindolone KAE609 (Cipargamin) To Assess Its Safety, Tolerability, and Pharmacokinetics in Healthy Adult Volunteers

This first-in-human randomized, double-blind, placebo-controlled, ascending-single and -multiple oral dose study was designed to evaluate the safety, tolerability, and pharmacokinetics in healthy volunteers of KAE609 (cipargamin; formerly NITD609), a spiroindolone now in trials for malaria treatment...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Leong, F. Joel, Li, Ruobing, Jain, Jay Prakash, Lefèvre, Gilbert, Magnusson, Baldur, Diagana, Thierry T., Pertel, Peter
التنسيق: Artigo
اللغة:Inglês
منشور في: American Society for Microbiology 2014
الموضوعات:
Clinical Therapeutics
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC4187895/
https://ncbi.nlm.nih.gov/pubmed/25114127
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.03393-14
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة